Expression of heparanase, Mdm2, and erbB2 in ovarian cancer

被引:0
|
作者
Ginath, S
Menczer, J
Friedmann, Y
Aingorn, H
Aviv, A
Tajima, K
Dantes, A
Glezerman, M
Vlodavsky, I
Amsterdam, A [1 ]
机构
[1] Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel
[2] Holon & Sackler Fac Med, Edith Wolfson Med Ctr, Gynecol Oncol Unit, Dept Obstet & Gynecol, Tel Aviv, Israel
[3] Hebrew Univ Jerusalem, Hadassah Hosp, Dept Oncol, IL-91120 Jerusalem, Israel
关键词
heparanase; Mdm2; erbB2; apoptosis; ovarian cancer;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Ovarian cancer is the most lethal of gynecological malignancies. Yet early diagnosis and prognosis are far from being satisfactory. Degradation of heparan sulfate proteoglycans by heparanase appears to play an important role in the invasiveness of tumor cells through the basement membrane and into the extracellular matrix. Recent cloning of the heparanase gene and generation of monoclonal antibodies against the enzyme permit to examine tumor cell expression of the enzyme. The aim of the present study was to assess heparanase activity and localization in various subtypes of epithelial ovarian cancer in correlation with oncogene expression. Histologically confirmed malignant ovarian tissue from ten women and tissue from 2 benign ovarian tumors and 4 normal ovaries were assessed for heparanase presence, activity and localization, incidence of apoptosis and expression of the oncogenes erbB2 and Mdm2. Heparanase immunohistostaining and activity were present in mucinous carcinomas and were more intense than in endometrioid and in serous carcinomas. The lowest activity was observed in benign ovarian tumors and normal ovaries. In ovarian carcinomas the enzyme was intensely concentrated in the cytoplasm of the cancerous cells. In contrast, in normal ovaries and benign tumors the enzyme was predominantly localized in endothelial cells lining blood capillaries. The rate of apoptosis was considerably higher in mucinous and endometrioid carcinomas, and was lower in serous and primary peritoneal carcinomas. Extremely high concentration of heparanase was often demonstrated in apoptotic cells. Endometrioid and serous carcinomas showed high expression of Mdm2 and erbB2 while mucinous carcinomas showed low expression. In benign ovarian tumors and normal ovaries the expression of both oncoproteins was extremely low. In conclusion ovarian carcinomas demonstrate higher levels of heparanase than benign tumors and normal ovaries suggesting that the enzyme may play an important role in metastatic spread of the cancerous cells. Apoptosis may be a significant part of the mechanism of the enzyme release into the extacellular space. Although heparanase activity seems to play an essential role in tumor progression, expression of oncogenes, such as erbB2 and Mdm2 seems to play the dominant role in the development of ovarian cancer.
引用
收藏
页码:1133 / 1144
页数:12
相关论文
共 50 条
  • [41] Extracellular domain ERBB2 (ERBB2 ECD+) mutations in urothelial bladder cancer (UBC).
    Basin, Michael
    Jacob, Joseph M.
    Bratslavsky, Gennady
    Grivas, Petros
    Spiess, Philippe E.
    Li, Roger
    Necchi, Andrea
    Pavlick, Dean C.
    Huang, Richard S. P.
    Lin, Douglas I.
    Danziger, Natalie
    Sokol, Ethan
    Sivakumar, Smruthy
    Ross, Jeffrey S.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [42] Expression of ErbB2 and ErbB3 in Non-Small Cell Lung Cancer
    Salcedo, M. T.
    Montero, M. A.
    Hernandez-Losa, J.
    Teixido, C.
    Allende, H.
    Felip, E.
    Murtra-Garrell, N.
    Pallisa, E.
    Canela, M.
    Ramon y Cajal, S.
    Tallada, N.
    LABORATORY INVESTIGATION, 2012, 92 : 489A - 489A
  • [43] MDM2 expression in normal and pathological skin
    Augias, D
    Dazard, JE
    BassetSeguin, N
    Neel, H
    Guilhou, JJ
    Piette, J
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1996, 107 (02) : C6 - C6
  • [44] Expression of MDM2 during mammary tumorigenesis
    Pinkas, J
    Naber, SP
    Butel, JS
    Medina, D
    Jerry, DJ
    INTERNATIONAL JOURNAL OF CANCER, 1999, 81 (02) : 292 - 298
  • [45] Expression of ErbB2 and ErbB3 in Non-Small Cell Lung Cancer
    Salcedo, M. T.
    Montero, M. A.
    Hernandez-Losa, J.
    Teixido, C.
    Allende, H.
    Felip, E.
    Murtra-Garrell, N.
    Pallisa, E.
    Canela, M.
    Ramon y Cajal, S.
    Tallada, N.
    MODERN PATHOLOGY, 2012, 25 : 489A - 489A
  • [46] Inhibition of MDM2 homodimerization by XIAP IRES stabilizes MDM2, influencing cancer cell survival
    Tao Liu
    Hailong Zhang
    Jing Xiong
    Sha Yi
    Lubing Gu
    Muxiang Zhou
    Molecular Cancer, 14
  • [47] MDM2 expression during mammary tumorigenesis
    Pinkas, J
    He, C
    Jerry, DJ
    Naber, SP
    MODERN PATHOLOGY, 1998, 11 (01) : 165A - 165A
  • [48] Genetic alterations and expression of erbB2 family members EGFR and erbB2 in MPNST, and implications for targeted therapy
    Holtkamp, N.
    Malzer, E.
    Zietsch, J.
    Okuducu, A. F.
    Mucha, J.
    Mawrin, C.
    Mautner, V.-F.
    Schildhaus, H-U
    von Deimling, A.
    ACTA NEUROPATHOLOGICA, 2007, 114 (03) : 315 - 316
  • [49] Expression of ERBB2 and BCL-2 in synovial sarcoma
    Krsková, Lenka
    Hilská, Irena
    Augustiñaková, Alena
    Kalinová, Markéta
    Mrhalová, Marcela
    Neradová, Marie
    Kodet, Roman
    MODERN PATHOLOGY, 2006, 19 : 181 - 181
  • [50] Genetic alterations in breast cancer associated with MDM2 dependency and sensitivity to the MDM2 inhibitor milademetan
    Bidard, Francois-Clement
    Roufai, Diana Bello
    Medford, Arielle J.
    Tirunagaru, Vijaya
    Doebele, Robert C.
    Bardia, Aditya
    CANCER RESEARCH, 2023, 83 (05)